Welcome to our dedicated page for Innovent Biologi news (Ticker: IVBIY), a resource for investors and traders seeking the latest updates and insights on Innovent Biologi stock.
The news feed for INNOVENT BIOLGCS UNSP/ADR (IVBIY) aggregates company press releases and media updates from Innovent Biologics, Inc., a biopharmaceutical company focused on oncology, cardiovascular and metabolic, autoimmune and ophthalmology diseases. These announcements provide insight into clinical trial progress, regulatory milestones, product approvals and corporate strategy that can influence how investors and observers view IVBIY.
Recent news highlights include multiple updates on mazdutide, a dual GCG/GLP-1 receptor agonist licensed from Eli Lilly for development in China. Innovent has reported National Medical Products Administration approvals for mazdutide in chronic weight management for adults with overweight or obesity and for glycemic control in adults with type 2 diabetes, along with Phase 3 data from the GLORY and DREAMS clinical programs. Other cardiovascular and metabolic pipeline news covers tigulixostat, a xanthine oxidase inhibitor for gout, and IBI3032, an oral GLP-1 receptor agonist with U.S. FDA IND approval for Phase 1 trials.
Oncology news items describe the development of IBI363, a PD-1/IL-2α-bias fusion protein, including U.S. FDA clearance of an IND for a global Phase 3 trial in immunotherapy-resistant squamous non-small cell lung cancer and data presented at major oncology conferences. Additional coverage includes IBI343, an anti-CLDN18.2 ADC with Phase 1 results in gastric/gastroesophageal junction adenocarcinoma published in Nature Medicine and the launch of multi-regional Phase 3 studies.
Investors following IVBIY can use this page to review updates on Innovent’s broader pipeline, such as picankibart for psoriasis, IBI324 for retinal diseases, and other marketed products mentioned in interim results and R&D day communications. Bookmark this news section to monitor how clinical data releases, regulatory decisions and partnership announcements may shape the company’s long-term development and commercialization plans.
Innovent Biologics (HKEX: 01801) and WeComput have announced a strategic partnership to advance AI-driven drug discovery and development. The collaboration aims to combine their respective strengths and technologies to accelerate the drug R&D process using AI technology. Innovent Academy will utilize WeComput's WeMol molecular design platform to enhance its computing infrastructure, while WeMol will integrate NVIDIA's BioNeMo to expand Innovent's AI systems' computing capability.
This partnership is expected to create a comprehensive, efficient, and intelligent AI-driven drug discovery system. The collaboration aims to reduce costs, shorten R&D cycles, and improve success rates in drug development, ultimately delivering more innovative treatments to patients.
Innovent Biologics (HKEX: 01801) announces that the Phase 3 clinical trial (DREAMS-1) of mazdutide, a GLP-1R and GCGR dual agonist, in Chinese adults with type 2 diabetes (T2D) met its primary endpoint and key secondary endpoints. The study showed superior glycemic control and weight loss compared to placebo. At week 24, HbA1c reduction in the mazdutide 4 mg (1.57%) and 6 mg (2.15%) groups was significantly better than placebo (0.14%). Mazdutide also demonstrated multiple cardiometabolic benefits and a favorable safety profile.
Innovent plans to submit a new drug application (NDA) for mazdutide to treat T2D to China's NMPA soon, following its first NDA for chronic weight management in February 2024. The DREAMS-1 results, along with the previously successful DREAMS-2 trial, provide strong evidence for mazdutide's efficacy in T2D treatment.
Innovent Biologics has launched an Environmental, Social, and Governance (ESG) website, emphasizing its commitment to sustainable development and corporate responsibility. The platform showcases the company's progress and achievements in governance, health, product quality, employee empowerment, and ecological stewardship. Innovent's key highlights include:
Governance: Transparent business practices and robust risk management.
Healthcare: Innovent's innovative drug development portfolio includes 36 assets and 10 launched products, benefiting over 2.5 million patients.
Quality: A robust quality management system with 140,000 liters of production capacity.
Employees: A diverse and inclusive work environment with over 50% female employees and a 98% satisfaction rate.
Ecology: ISO14001 certification and proactive climate change strategies.
CEO Dr. Michael Yu reaffirms the company's dedication to transparency and sustainability, aiming to create long-term value for stakeholders. For more details, visit the ESG website at Innovent's official page.
Innovent Biologics and IASO Bio have announced a strategic collaboration in cell therapy. IASO Bio will acquire Innovent's rights to FUCASO® (Equecabtagene Autoleucel), including global commercial rights and intellectual property licenses. Innovent will gain an 18% stake in IASO Bio. FUCASO®, a CAR-T product approved in China and the world's first fully human CAR-T product, will be developed, manufactured, and commercialized by IASO Bio. This partnership aims to enhance resources and team integration, focusing on advancing innovative therapeutic solutions.
Innovent Biologics presented its latest Phase 1 clinical data for the anti-CLDN18.2 ADC (IBI343) at the ESMO Gastrointestinal Cancers Congress 2024. This treatment targets advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJ AC) patients with high CLDN18.2 expression. Results showed an ORR of 36.7% and DCR of 93.3% at 6 mg/kg, and an ORR of 47.1% and DCR of 88.2% at 8 mg/kg. The median progression-free survival at 6 mg/kg was 6.8 months. Most treatment-related adverse events were grade 1-2, with low grade 3 gastrointestinal toxicities and no interstitial lung disease. Innovent plans to explore IBI343 in combination therapies and other tumor types.
Innovent Biologics provided updates on its Mazdutide GLORY-1 study and the company's biomedicine pipeline at an investor conference call on June 25, 2024. The Phase 3 GLORY-1 study, presented at the 2024 ADA Scientific Meeting, showed significant weight loss and liver fat reduction among overweight or obese adults in China. Mazdutide, a GLP-1R/GCGR dual agonist, reduced weight by 14.3% and liver fat by 80.2% after 48 weeks, also improving multiple cardiovascular risk indicators. The treatment proved safe and well-tolerated. Innovent is pursuing additional indications for mazdutide and advancing its cardiovascular and metabolic disease pipeline with products like SINTBILO, IBI128, and IBI3016. The company is also progressing in autoimmune and ophthalmological treatments with candidates like SULINNO, picankibart, and IBI311.
Innovent Biologics presented results from its first Phase 3 study of the drug mazdutide for weight management at the ADA Scientific Sessions 2024. The GLORY-1 study, involving 610 Chinese adults, demonstrated significant weight loss, reduced liver fat, and improved cardiometabolic risk factors compared to placebo. Mazdutide achieved weight reduction endpoints, with differences in mean weight loss reaching -14.31% at 48 weeks for the highest dose. The drug also showed favorable safety and tolerability. The new drug application for mazdutide is under review by China's National Medical Products Administration, with potential to offer a new treatment for obesity and related conditions.
Innovent Biologics announced results from their Phase 3 GLORY-1 study, revealing a significant reduction in liver fat content using mazdutide, a GLP-1R and GCGR dual agonist. The study involved 610 Chinese adults with obesity or overweight, showing an average liver fat reduction of 80.2% in participants with a baseline LFC ≥10%. The 48-week trial demonstrated dose-dependent improvements in liver fat content, body weight, and other metabolic parameters, outperforming placebo. These findings suggest mazdutide's potential in treating MAFLD and MASH.
Innovent Biologics shared updates on its oncology pipeline during a recent investor meeting. The company highlighted the progress of multiple cancer drug candidates, including IBI363, IBI343, and IBI389. IBI363, a PD-1/IL-2 bispecific antibody, showed promising results in various cancer types. IBI343, the first ADC drug with initial breakthrough efficacy in pancreatic cancer, demonstrated a 40% ORR in Phase 1 trials. IBI389, a bispecific antibody targeting CLDN18.2/CD3, showed notable anti-tumor activity in pancreatic and gastric cancers, with a 29.6% ORR among participants. Innovent aims to advance these drugs through further clinical trials, leveraging its
Innovent Biologics presented new clinical data of IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, at the 2024 ESMO Virtual Plenary. The Phase 1 study showed promising results in various advanced solid tumors, including NSCLC, melanoma, and colorectal cancer. Over 300 subjects were treated with IBI363, showing good tolerability and safety. Notable efficacy was observed in IO-treated squamous NSCLC and IO-naïve mucosal melanoma. The overall objective response rate (ORR) and disease control rate (DCR) for various doses were highlighted, with the 3mg/kg dose showing the highest efficacy. Innovent plans to continue exploring IBI363's potential in further studies.